Zelluna Immunotherapy is described in press coverage as an immunotherapy company. The article reporting the fundraising does not detail the company’s specific products, pipeline, or therapeutic targets. No operating metrics, revenue, or user/customer figures were provided. The coverage also does not reference the company’s founding year or location. Apart from the reported 58.2 million raise, no further financial or strategic plans were disclosed in the article.

Total raised

$14M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2020